The 37th International Conference on Antiviral Research (ICAR) was held in Gold Coast, Australia, May 20-24, 2024. ICAR 2024 featured over 75 presentations along with two poster sessions and special events, including those specifically tailored for trainees and early-career scientists. The meeting served as a platform for the exchange of cutting-edge research, with presentations and discussions covering novel antiviral compounds, vaccine development, clinical trials, and therapeutic advancements. A comprehensive array of topics in antiviral science was covered, from the latest breakthroughs in antiviral drug development to innovative strategies for combating emerging viral threats. The keynote presentations provided fascinating insight into two diverse areas fundamental to medical countermeasure development and use, including virus emergence at the human-animal interface and practical considerations for bringing antivirals to the clinic. Additional sessions addressed a variety of timely post-pandemic topics, such as the hunt for broad spectrum antivirals, combination therapy, pandemic preparedness, application of in silico tools and AI in drug discovery, the virosphere, and more. Here, we summarize all the presentations and special sessions of ICAR 2024 and introduce the 38th ICAR, which will be held in Las Vegas, USA, March 17-21, 2025.

Baker Institute and Department of Microbiology and Immunology Cornell University Ithaca NY USA

Centre International de Recherche en Infectiologie Inserm_U1111 CNRS_UMR5308 Université Claude Bernard Lyon 1 F 69007 Lyon France

Department of Chemistry and Biochemistry University of Maryland Baltimore County Baltimore MD USA

Department of Epidemiology University of North Carolina at Chapel Hill Chapel Hill NC USA; Department of Microbiology and Immunology University of North Carolina School of Medicine Chapel Hill NC USA; Rapidly Emerging Antiviral Drug Development Initiative University of North Carolina at Chapel Hill Chapel Hill NC USA

Department of Microbiology and Immunology SUNY Upstate Medical University Syracuse NY USA

Division of the Laboratory of Biochemical Pharmacology Department of Pediatrics Emory University School of Medicine Children's Healthcare of Atlanta Atlanta GA USA

Evotec US Princeton NJ USA

Fred Hutchinson Cancer Research Center Vaccine and Infectious Diseases Division Seattle WA USA; Division of Allergy and Infectious Diseases University of Washington Seattle WA USA

Gilead Sciences Inc Foster City CA USA

Innovative Molecules GmbH Lipowsky Str 10 81373 Munich Bavaria Germany

Institute for Antiviral Research and Department of Animal Dairy and Veterinary Sciences Utah State University Logan UT USA

Institute for Biomedicine and Glycomics Griffith University Southport QLD Australia

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nám 2 160 00 Prague Czech Republic

Organic Chemistry Department of Chemistry Faculty of Sciences University of Hamburg Martin Luther King Platz 6 Hamburg Germany

PostEra Inc 1 Broadway Cambridge MA USA

Viral Special Pathogens Branch Division of High Consequence Pathogens and Pathology Centers for Disease Control and Prevention Atlanta GA USA

Virus Host Interactions and Therapeutic Approaches Research Group Department of Microbiology Immunology and Transplantation Rega Institute for Medical Research KU Leuven Leuven Belgium

Zobrazit více v PubMed

Adam A, Kalveram B, Chen JY-C, Yeung J, Rodriguez L, Singh A, Shi P-Y, Xie X, Wang T, 2023. A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity. NPJ vaccines 8, 160. 10.1038/s41541-023-00753-4. PubMed DOI PMC

Ahmed-Belkacem R, Hausdorff M, Delpal A, Sutto-Ortiz P, Colmant AMG, Touret F, Ogando NS, Snijder EJ, Canard B, Coutard B, Vasseur J-J, Decroly E, Debart F, 2022. Potent inhibition of SARS-CoV-2 nsp14 N7-methyltransferase by sulfonamide-based bisubstrate analogues. J. Med. Chem 65, 6231–6249. 10.1021/acs.jmedchem.2c00120. PubMed DOI

Aida-Ficken V, Kelly JA, Chatterjee P, Jenks MH, McMullan LK, Albariño CG, Montgomery JM, Seley-Radtke KL, Spiropoulou CF, Flint M, 2024. Identification of a macrocyclic compound targeting the Lassa virus polymerase. Antivir. Res, 105923 10.1016/j.antiviral.2024.105923. PubMed DOI

Alqarni S, Cooper L, Galvan Achi J, Bott R, Sali VK, Brown A, Santarsiero BD, Krunic A, Manicassamy B, Peet NP, Zhang P, Thatcher GRJ, Gaisina IN, Rong L, Moore TW, 2022. Synthesis, optimization, and structure-activity relationships of imidazo[1,2-a]pyrimidines as inhibitors of group 2 influenza A viruses. J. Med. Chem 65, 14104–14120. 10.1021/acs.jmedchem.2c01329. PubMed DOI

Alves VM, Bobrowski T, Melo-Filho CC, Korn D, Auerbach S, Schmitt C, Muratov EN, Tropsha A, 2021. QSAR modeling of SARS-CoV Mpro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS-CoV-2. Mol. Inform 40, e2000113. 10.1002/minf.202000113. PubMed DOI

Alves VM, Borba JVB, Braga RC, Korn DR, Kleinstreuer N, Causey K, Tropsha A, Rua D, Muratov EN, 2022. PreS/MD: predictor of sensitization hazard for chemical substances released from medical devices. Toxicol. Sci 189, 250–259. 10.1093/toxsci/kfac078. PubMed DOI PMC

Alves VM, Yasgar A, Wellnitz J, Rai G, Rath M, Braga RC, Capuzzi SJ, Simeonov A, Muratov EN, Zakharov AV, Tropsha A, 2023. Lies and liabilities: computational assessment of high-throughput screening hits to identify artifact compounds. J. Med. Chem 66, 12828–12839. 10.1021/acs.jmedchem.3c00482. PubMed DOI PMC

Andrei G, Carter K, Janeba Z, Sampath A, Schang LM, Tarbet EB, Vere Hodge RA, Bray M, Esté JA, 2017. Highlights of the 30th international conference on antiviral research. Antivir. Res 145, 184–196. 10.1016/j.antiviral.2017.07.017. PubMed DOI PMC

Arandjelovic P, Kim Y, Cooney JP, Preston SP, Doerflinger M, McMahon JH, Garner SE, Zerbato JM, Roche M, Tumpach C, Ong J, Sheerin D, Smyth GK, Anderson JL, Allison CC, Lewin SR, Pellegrini M, 2023. Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice. Cell reports. Méd 4, 101178. 10.1016/j.xcrm.2023.101178. PubMed DOI PMC

Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pântea V, Lazar S, Placinta G, Gherlan GS, Bogomolov P, Stepanova T, Morozov V, Syutkin V, Sagalova O, Manuilov D, Mercier R-C, Ye L, Da BL, Chee G, Lau AH, Osinusi A, Bourliere M, Ratziu V, Pol S, Hilleret M-N, Zoulim F, Didier S, 2024. Bulevirtide combined with pegylated interferon for chronic hepatitis D. N. Engl. J. Med 10.1056/NEJMoa2314134. PubMed DOI

Beasley J-MT, Korn DR, Popov KI, Dumproff RL, Sessions ZL, Rath MK, Alves VM, Causey K, Rua D, Muratov EN, Tropsha A, 2022. Integrated approach to elucidate metal-implant related adverse outcome pathways. Regul. Toxicol. Pharmacol 136, 105277. 10.1016/j.yrtph.2022.105277. PubMed DOI

Ben-Shimol S, Landau D, Zilber S, Greenberg D, 2013. Parainfluenza virus type 3 outbreak in a neonatal nursery. Clin. Pediatr. (Phila) 52, 866–870. 10.1177/0009922812441674. PubMed DOI

Beumer J, Geurts MH, Lamers MM, Puschhof J, Zhang J, van der Vaart J, Mykytyn AZ, Breugem TI, Riesebosch S, Schipper D, van den Doel PB, de Lau W, Pleguezuelos-Manzano C, Busslinger G, Haagmans BL, Clevers H, 2021. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. Nat. Commun 12, 5498. 10.1038/s41467-021-25729-7. PubMed DOI PMC

Bobrowski T, Chen L, Eastman RT, Itkin Z, Shinn P, Chen CZ, Guo H, Zheng W, Michael S, Simeonov A, Hall MD, Zakharov AV, Muratov EN, 2021. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol. Ther 29, 873–885. 10.1016/j.ymthe.2020.12.016. PubMed DOI PMC

Bobrowski T, Melo-Filho CC, Korn D, Alves VM, Popov KI, Auerbach S, Schmitt C, Moorman NJ, Muratov EN, Tropsha A, 2020. Learning from history: do not flatten the curve of antiviral research. Drug Discov. Today 25, 1604–1613. 10.1016/j.drudis.2020.07.008. PubMed DOI PMC

Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN, 2023. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science 382, eabo7201. 10.1126/science.abo7201. PubMed DOI PMC

Bochkov YA, Watters K, Ashraf S, Griggs TF, Devries MK, Jackson DJ, Palmenberg AC, Gern JE, 2015. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc. Natl. Acad. Sci. USA 112, 5485–5490. 10.1073/pnas.1421178112. PubMed DOI PMC

Bochkov YA, Watters K, Basnet S, Sijapati S, Hill M, Palmenberg AC, Gern JE, 2016. Mutations in VP1 and 3A proteins improve binding and replication of rhinovirus C15 in HeLa-E8 cells. Virology 499, 350–360. 10.1016/j.virol.2016.09.025. PubMed DOI PMC

Borba JVB, Alves VM, Braga RC, Korn DR, Overdahl K, Silva AC, Hall SUS, Overdahl E, Kleinstreuer N, Strickland J, Allen D, Andrade CH, Muratov EN, Tropsha A, 2022. STopTox: an in silico alternative to animal testing for acute systemic and topical toxicity. Environ. Health Perspect 130. 10.1289/EHP9341. PubMed DOI PMC

Brancale A, Carter K, Delang L, Deval J, Durantel D, Gentry BG, Jordan R, Julander JG, Lo MK, Pérez-Pérez M-JJ, Schang LM, Seley-Radtke KL, Shi P-YY, Vasudevan SG, Whitley RJ, Spengler JR, 2022. Meeting report: 34th international conference on antiviral research. Antivir. Chem. Chemother 30, 20402066221130852. 10.1177/20402066221130853. PubMed DOI PMC

Branche AR, Falsey AR, 2016. Parainfluenza virus infection. Semin. Respir. Crit. Care Med 37, 538–554. 10.1055/s-0036-1584798. PubMed DOI PMC

Bray M, Andrei G, Ballana E, Carter K, Durantel D, Gentry B, Janeba Z, Moffat J, Oomen CJ, Tarbet B, Riveira-Muñoz E, Esté JA, International society for antiviral research, 2018. Meeting report: 31st international conference on antiviral research. Antivir. Res. 158, 88–102. doi:10.1016/j.antiviral.2018.08.002. PubMed DOI PMC

Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM, 2015. HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chem. Biol 10, 1831–1837. 10.1021/acschembio.5b00442. PubMed DOI PMC

Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo J-T, Block TM, Cuconati A, Guo H, 2012. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob. Agents Chemother 56, 4277–4288. 10.1128/AAC.00473-12. PubMed DOI PMC

Cai D, Yan R, Xu JZ, Zhang H, Shen S, Mitra B, Marchetti A, Kim ES, Guo H, 2020. Characterization of the termini of cytoplasmic hepatitis B virus deproteinated relaxed circular DNA. J. Virol 95. 10.1128/JVI.00922-20. PubMed DOI PMC

Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang Chunying, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R, Wang Chen, 2024. Oral simnotrelvir for adult patients with mild-to-moderate covid-19. N. Engl. J. Med 390, 230–241. 10.1056/NEJMoa2301425. PubMed DOI PMC

Carlin AF, Beadle JR, Clark AE, Gully KL, Moreira FR, Baric RS, Graham RL, Valiaeva N, Leibel SL, Bray W, McMillan RE, Freshman JE, Garretson AF, McVicar RN, Rana T, Zhang X-Q, Murphy JA, Schooley RT, Hostetler KY, 2023. 1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of oral V2043 in a mouse model of SARS-CoV-2 infection and synthesis and antiviral evaluation of additional phospholipid esters with enhanced anti-SARS-CoV-2 activity. J. Med. Chem 66, 5802–5819. 10.1021/acs.jmedchem.3c00046. PubMed DOI PMC

Chan KWK, Watanabe S, Jin JY, Pompon J, Teng D, Alonso S, Vijaykrishna D, Halstead SB, Marzinek JK, Bond PJ, Burla B, Torta F, Wenk MR, Ooi EE, Vasudevan SG, 2019. A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice. Sci. Transl. Med 11. 10.1126/scitranslmed.aat7726. PubMed DOI

Chappell KJ, Mordant FL, Amarilla AA, Modhiran N, Liang B, Li Z, Wijesundara DK, Lackenby JA, Griffin P, Bennet JK, Hensen L, Zhang W, Nguyen THO, Tran MH, Tapley P, Barnes J, Reading PC, Kedzierska K, Ranasinghe C, Subbarao K, Watterson D, Young PR, Munro TP, 2023. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial. EBioMedicine 97, 104842. 10.1016/j.ebiom.2023.104842. PubMed DOI PMC

Chen Y, Yao Y, Zhao K, Liu C, Yuan Y, Sun H, Huang D, Zheng Y, Zhou Y, Chen J, Wang Y, Wu C, Zhang B, Guan Y, Li F, Pei R, Chen X, 2022. DNA repair factor poly(ADP-ribose) polymerase 1 is a proviral factor in hepatitis B virus covalently closed circular DNA formation. J. Virol 96, e0058522. 10.1128/jvi.00585-22. PubMed DOI PMC

Chew BLA, Ngoh ANQ, Phoo WW, Chan KWK, Ser Z, Tulsian NK, Lim SS, Weng MJG, Watanabe S, Choy MM, Low J, Ooi EE, Ruedl C, Sobota RM, Vasudevan SG, Luo D, 2024. Secreted dengue virus NS1 from infection is predominantly dimeric and in complex with high-density lipoprotein. Elife 12. 10.7554/eLife.90762. PubMed DOI PMC

Chiramel AI, Meyerson NR, McNally KL, Broeckel RM, Montoya VR, Méndez-Solís O, Robertson SJ, Sturdevant GL, Lubick KJ, Nair V, Youseff BH, Ireland RM, Bosio CM, Kim K, Luban J, Hirsch VM, Taylor RT, Bouamr F, Sawyer SL, Best SM, 2019. TRIM5α restricts flavivirus replication by targeting the viral protease for proteasomal degradation. Cell Rep. 27, 3269–3283.e6. 10.1016/j.celrep.2019.05.040. PubMed DOI PMC

Choi SG, Olivet J, Cassonnet P, Vidalain P-O, Luck K, Lambourne L, Spirohn K, Lemmens I, Dos Santos M, Demeret C, Jones L, Rangarajan S, Bian W, Coutant EP, Janin YL, van der Werf S, Trepte P, Wanker EE, De Las Rivas J, Tavernier J, Twizere J-C, Hao T, Hill DE, Vidal M, Calderwood MA, Jacob Y, 2019. Maximizing binary interactome mapping with a minimal number of assays. Nat. Commun 10, 3907. 10.1038/s41467-019-11809-2. PubMed DOI PMC

Cline TD, Karlsson EA, Seufzer BJ, Schultz-Cherry S, 2013. The hemagglutinin protein of highly pathogenic H5N1 influenza viruses overcomes an early block in the replication cycle to promote productive replication in macrophages. J. Virol 87, 1411–1419. 10.1128/JVI.02682-12. PubMed DOI PMC

Cong Y, Lentz MR, Lara A, Alexander I, Bartos C, Bohannon JK, Hammoud D, Huzella L, Jahrling PB, Janosko K, Jett C, Kollins E, Lackemeyer M, Mollura D, Ragland D, Rojas O, Solomon J, Xu Z, Munster V, Holbrook MR, 2017. Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus. PLoS Neglected Trop. Dis 11, e0005532. 10.1371/journal.pntd.0005532. PubMed DOI PMC

Cox RG, Livesay SB, Johnson M, Ohi MD, Williams JV, 2012. The human metapneumovirus fusion protein mediates entry via an interaction with RGD-binding integrins. J. Virol 86, 12148–12160. 10.1128/JVI.01133-12. PubMed DOI PMC

Cox RM, Wolf JD, Lieber CM, Sourimant J, Lin MJ, Babusis D, DuPont V, Chan J, Barrett KT, Lye D, Kalla R, Chun K, Mackman RL, Ye C, Cihlar T, Martinez-Sobrido L, Greninger AL, Bilello JP, Plemper RK, 2021. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat. Commun 12, 6415. 10.1038/s41467-021-26760-4. PubMed DOI PMC

Cox S, Ahalt SC, Balhoff J, Bizon C, Fecho K, Kebede Y, Morton K, Tropsha A, Wang P, Xu H, 2020. Visualization environment for federated knowledge graphs: development of an interactive biomedical query language and web application interface. JMIR Med. Informatics 8, e17964. 10.2196/17964. PubMed DOI PMC

Culyba M, Hwang Y, Attar S, Madrid PB, Bupp J, Huryn D, Sanchez L, Grobler J, Miller MD, Bushman FD, 2012. Bulged DNA substrates for identifying poxvirus resolvase inhibitors. Nucleic Acids Res. 40, e124. 10.1093/nar/gks325. PubMed DOI PMC

Dai W, Jochmans D, Xie H, Yang H, Li J, Su H, Chang D, Wang J, Peng J, Zhu L, Nian Y, Hilgenfeld R, Jiang H, Chen K, Zhang L, Xu Y, Neyts J, Liu H, 2022. Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2. J. Med. Chem 65, 2794–2808. 10.1021/acs.jmedchem.0c02258. PubMed DOI

Dai W, Zhang B, Jiang X-M, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, Li C, Li Y, Bai F, Wang H, Cheng X, Cen X, Hu S, Yang X, Wang J, Liu X, Xiao G, Jiang H, Rao Z, Zhang L-K, Xu Y, Yang H, Liu H, 2020. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331–1335. 10.1126/science.abb4489. PubMed DOI PMC

Davies KA, Welch SR, Jain S, Sorvillo TE, Coleman-McCray JD, Montgomery JM, Spiropoulou CF, Albariño C, Spengler JR, 2023. Fluorescent and bioluminescent reporter mouse-adapted Ebola viruses maintain pathogenicity and can Be visualized in vivo. J. Infect. Dis 228, S536–S547. 10.1093/infdis/jiad136. PubMed DOI PMC

Diab A, Foca A, Zoulim F, Durantel D, Andrisani O, 2018. The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: implications for the development of HBc-targeting antivirals. Antivir. Res 149, 211–220. 10.1016/j.antiviral.2017.11.015. PubMed DOI PMC

Du R, Cheng H, Cui Q, Peet NP, Gaisina IN, Rong L, 2021. Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins. Antivir. Res 186, 105013. 10.1016/j.antiviral.2021.105013. PubMed DOI PMC

Du S, Hu X, Menéndez-Arias L, Zhan P, Liu X, 2024. Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges. Drug Resist. Updates 73, 101053. 10.1016/j.drup.2024.101053. PubMed DOI

Erasmus JH, Khandhar AP, O’Connor MA, Walls AC, Hemann EA, Murapa P, Archer J, Leventhal S, Fuller JT, Lewis TB, Draves KE, Randall S, Guerriero KA, Duthie MS, Carter D, Reed SG, Hawman DW, Feldmann H, Gale M, Veesler D, Berglund P, Fuller DH, 2020. An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med 12. 10.1126/scitranslmed.abc9396. PubMed DOI PMC

Esmaeili S, Owens K, Wagoner J, Polyak SJ, White JM, Schiffer JT, 2024. A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy. Nat. Commun 15, 5478. 10.1038/s41467-024-49458-9. PubMed DOI PMC

Flores Cortes E, Saddoris SM, Owens AK, Gibeault R, Depledge DP, Schang LM, 2024. Histone H2A variant H2A.B is enriched in transcriptionally active and replicating HSV-1 lytic chromatin. J. Virol 98. 10.1128/jvi.02015-23. PubMed DOI PMC

Gaisina I, Li P, Du R, Cui Q, Dong M, Zhang C, Manicassamy B, Caffrey M, Moore T, Cooper L, Rong L, 2024. An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil. Sci. Adv 10, eadk9004. 10.1126/sciadv.adk9004. PubMed DOI PMC

Gaisina IN, Peet NP, Cheng H, Li P, Du R, Cui Q, Furlong K, Manicassamy B, Caffrey M, Thatcher GRJ, Rong L, 2020. Optimization of 4-aminopiperidines as inhibitors of influenza A viral entry that are synergistic with oseltamivir. J. Med. Chem 63, 3120–3130. 10.1021/acs.jmedchem.9b01900. PubMed DOI PMC

Gao S, Song L, Sylvester K, Mercorelli B, Loregian A, Toth K, Weiße RH, Useini A, Sträter N, Yang M, Ye B, Tollefson AE, Müller CE, Liu X, Zhan P, 2023. Design, synthesis, and biological evaluation of trisubstituted piperazine derivatives as noncovalent severe acute respiratory syndrome coronavirus 2 main protease inhibitors with improved antiviral activity and favorable druggability. J. Med. Chem 66, 16426–16440. 10.1021/acs.jmedchem.3c01876. PubMed DOI

Gao S, Sylvester K, Song L, Claff T, Jing L, Woodson M, Weiße RH, Cheng Y, Schäkel L, Petry M, Gütschow M, Schiedel AC, Sträter N, Kang D, Xu S, Toth K, Tavis J, Tollefson AE, Müller CE, Liu X, Zhan P, 2022. Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity. J. Med. Chem 65, 13343–13364. 10.1021/acs.jmedchem.2c01146. PubMed DOI

Garcia AD, Moss B, 2001. Repression of vaccinia virus Holliday junction resolvase inhibits processing of viral DNA into unit-length genomes. J. Virol 75, 6460–6471. 10.1128/JVI.75.14.6460-6471.2001. PubMed DOI PMC

Garnsey MR, Robinson MC, Nguyen LT, Cardin R, Tillotson J, Mashalidis E, Yu A, Aschenbrenner L, Balesano A, Behzadi A, Boras B, Chang JS, Eng H, Ephron A, Foley T, Ford KK, Frick JM, Gibson S, Hao L, Hurst B, Kalgutkar AS, Korczynska M, Lengyel-Zhand Z, Gao L, Meredith HR, Patel NC, Polivkova J, Rai D, Rose CR, Rothan H, Sakata SK, Vargo TR, Qi W, Wu H, Liu Y, Yurgelonis I, Zhang J, Zhu Y, Zhang L, Lee AA, 2024. Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model. bioRxiv. 10.1101/2024.01.26.577395. PubMed DOI PMC

Garrison AR, Shoemaker CJ, Golden JW, Fitzpatrick CJ, Suschak JJ, Richards MJ, Badger CV, Six CM, Martin JD, Hannaman D, Zivcec M, Bergeron E, Koehler JW, Schmaljohn CS, 2017. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS Neglected Trop. Dis 11, e0005908. 10.1371/journal.pntd.0005908. PubMed DOI PMC

Gillespie L, Gerstenberg K, Ana-Sosa-Batiz F, Parsons MS, Farrukee R, Krabbe M, Spann K, Brooks AG, Londrigan SL, Reading PC, 2016. DC-SIGN and L-SIGN are attachment factors that promote infection of target cells by human metapneumovirus in the presence or absence of cellular glycosaminoglycans. J. Virol 90, 7848–7863. 10.1128/JVI.00537-16. PubMed DOI PMC

Golden JW, Fitzpatrick CJ, Suschak JJ, Clements TL, Ricks KM, Sanchez-Lockhart M, Garrison AR, 2023. Induced protection from a CCHFV-M DNA vaccine requires CD8+ T cells. Virus Res. 334, 199173. 10.1016/j.virusres.2023.199173. PubMed DOI PMC

Guo F, Wu S, Julander J, Ma J, Zhang X, Kulp J, Cuconati A, Block TM, Du Y, Guo J-T, Chang J, 2016. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J. Virol 90, 10774–10788. 10.1128/JVI.01253-16. PubMed DOI PMC

Guo F, Zhao X, Gill T, Zhou Y, Campagna M, Wang L, Liu F, Zhang P, DiPaolo L, Du Y, Xu X, Jiang D, Wei L, Cuconati A, Block TM, Guo J-T, Chang J, 2014. An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. Antivir. Res 107, 56–65. 10.1016/j.antiviral.2014.04.010. PubMed DOI PMC

Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo J-T, 2007. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J. Virol 81, 12472–12484. 10.1128/JVI.01123-07. PubMed DOI PMC

Guo H, Mao R, Block TM, Guo J-T, 2010. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J. Virol 84, 387–396. 10.1128/JVI.01921-09. PubMed DOI PMC

Hausdorff M, Delpal A, Barelier S, Nicollet L, Canard B, Touret F, Colmant A, Coutard B, Vasseur J-J, Decroly E, Debart F, 2023. Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases. Eur. J. Med. Chem 256, 115474. 10.1016/j.ejmech.2023.115474. PubMed DOI PMC

He W-T, Hou X, Zhao J, Sun J, He H, Si W, Wang J, Jiang Z, Yan Z, Xing G, Lu M, Suchard MA, Ji X, Gong W, He B, Li J, Lemey P, Guo D, Tu C, Holmes EC, Shi M, Su S, 2022. Virome characterization of game animals in China reveals a spectrum of emerging pathogens. Cell 185, 1117–1129.e8. 10.1016/j.cell.2022.02.014. PubMed DOI PMC

Hepatitis B Foundation, H.B.F., 2024. HBV foundation DrugWatch. https://www.hepb.org/treatment-and-management/drug-watch/, 7.7.24.

Hochuli JE, Jain S, Melo-Filho C, Sessions ZL, Bobrowski T, Choe J, Zheng J, Eastman R, Talley DC, Rai G, Simeonov A, Tropsha A, Muratov EN, Baljinnyam B, Zakharov AV, 2022. Allosteric binders of ACE2 are promising anti-SARS-CoV-2 agents. bioRxiv Prepr. Serv. Biol 10.1101/2022.03.15.484484. PubMed DOI PMC

Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonigk D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S, 2021. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine 65, 103255. 10.1016/j.ebiom.2021.103255. PubMed DOI PMC

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S, 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8. 10.1016/j.cell.2020.02.052. PubMed DOI PMC

Hosmillo M, Lu J, McAllaster MR, Eaglesham JB, Wang X, Emmott E, Domingues P, Chaudhry Y, Fitzmaurice TJ, Tung MK, Panas MD, McInerney G, Locker N, Wilen CB, Goodfellow IG, 2019. Noroviruses subvert the core stress granule component G3BP1 to promote viral VPg-dependent translation. Elife 8. 10.7554/eLife.46681. PubMed DOI PMC

Hu M, Depledge DP, Flores Cortes E, Breuer J, Schang LM, 2019. Chromatin dynamics and the transcriptional competence of HSV-1 genomes during lytic infections. PLoS Pathog. 15, e1008076. 10.1371/journal.ppat.1008076. PubMed DOI PMC

Hussein AFA, Cheng H, Tundup S, Antanasijevic A, Varhegyi E, Perez J, AbdulRahman EM, Elenany MG, Helal S, Caffrey M, Peet N, Manicassamy B, Rong L, 2020. Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus. Antivir. Res 177, 104782. 10.1016/j.antiviral.2020.104782. PubMed DOI PMC

Ianevski A, Giri AK, Aittokallio T, 2020. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488–W493. 10.1093/nar/gkaa216. PubMed DOI PMC

Inniss NL, Kozic J, Li F, Rosas-Lemus M, Minasov G, Rybáček J, Zhu Y, Pohl R, Shuvalova L, Rulíšek L, Brunzelle JS, Bednárová L, Štefek M, Kormaník JM, Andris E, Šebestík J, Li ASM, Brown PJ, Schmitz U, Saikatendu K, Chang E, Nencka R, Vedadi M, Satchell KJF, 2023. Discovery of a druggable, cryptic pocket in SARS-CoV-2 nsp16 using allosteric inhibitors. ACS Infect. Dis 9, 1918–1931. 10.1021/acsinfecdis.3c00203. PubMed DOI PMC

Isaacs A, Low YS, Macauslane KL, Seitanidou J, Pegg CL, Cheung STM, Liang B, Scott CAP, Landsberg MJ, Schulz BL, Chappell KJ, Modhiran N, Watterson D, 2023. Structure and antigenicity of divergent Henipavirus fusion glycoproteins. Nat. Commun 14, 3577. 10.1038/s41467-023-39278-8. PubMed DOI PMC

Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M, 2022. Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. Nat. Commun 13, 6100. 10.1038/s41467-022-33911-8. PubMed DOI PMC

Iyer K, Yan Z, Ross SR, 2024. Entry inhibitors as arenavirus antivirals. Front. Microbiol 15, 1382953. 10.3389/fmicb.2024.1382953. PubMed DOI PMC

Kainulainen MH, Spengler JR, Welch SR, Coleman-Mccray JADAD, Harmon JR, Klena JD, Nichol ST, Albariño CG, Spiropoulou CF, 2018. Use of a scalable replicon-particle vaccine to protect against lethal Lassa virus infection in the Guinea pig model. J. Infect. Dis 217, 1957–1966. 10.1093/infdis/jiy123. PubMed DOI PMC

Kaptein SJF, Goethals O, Kiemel D, Marchand A, Kesteleyn B, Bonfanti J-F, Bardiot D, Stoops B, Jonckers THM, Dallmeier K, Geluykens P, Thys K, Crabbe M, Chatel-Chaix L, Münster M, Querat G, Touret F, de Lamballerie X, Raboisson P, Simmen K, Chaltin P, Bartenschlager R, Van Loock M, Neyts J, 2021. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature 598, 504–509. 10.1038/s41586-021-03990-6. PubMed DOI

Kim ES, Zhou J, Zhang H, Marchetti A, van de Klundert M, Cai D, Yu X, Mitra B, Liu Y, Wang M, Protzer U, Guo H, 2022. Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA. PLoS Pathog. 18, e1010576. 10.1371/journal.ppat.1010576. PubMed DOI PMC

Kitamura K, Que L, Shimadu M, Koura M, Ishihara Y, Wakae K, Nakamura T, Watashi K, Wakita T, Muramatsu M, 2018. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathog. 14, e1007124. 10.1371/journal.ppat.1007124. PubMed DOI PMC

Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC, Janssen GMC, Ruben M, Overkleeft HS, van Veelen PA, Samborskiy DV, Kravchenko AA, Leontovich AM, Sidorov IA, Snijder EJ, Posthuma CC, Gorbalenya AE, 2015. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res. 43, 8416–8434. 10.1093/nar/gkv838. PubMed DOI PMC

Li H, Hwang Y, Perry K, Bushman F, Van Duyne GD, 2016. Structure and metal binding properties of a poxvirus resolvase. J. Biol. Chem 291, 11094–11104. 10.1074/jbc.M115.709139. PubMed DOI PMC

Liu Y, Zhang X, Liu J, Xia H, Zou J, Muruato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, Kalveram B, Bukreyev A, Ren P, Wang T, Menachery VD, Plante KS, Xie X, Weaver SC, Shi P-Y, 2022. Publisher Correction: a live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat. Commun 13, 6060. 10.1038/s41467-022-33878-6. PubMed DOI PMC

Lo MK, Jain S, Davies KA, Sorvillo TE, Welch SR, Coleman-McCray JD, Chatterjee P, Hotard AL, O’Neal T, Flint M, Ai H, Albariño CG, Spengler JR, Montgomery JM, Spiropoulou CF, 2024. Optimization of Bangladesh and Malaysian genotype recombinant reporter Nipah viruses for in vitro antiviral screening and in vivo disease modeling. Antiviral Res. 231, 106013. 10.1016/j.antiviral.2024.106013. PubMed DOI PMC

Lo MK, Peeples ME, Bellini WJ, Nichol ST, Rota PA, Spiropoulou CF, 2012. Distinct and overlapping roles of Nipah virus P gene products in modulating the human endothelial cell antiviral response. PLoS One 7, e47790. 10.1371/journal.pone.0047790. PubMed DOI PMC

Londrigan SL, Short KR, Ma J, Gillespie L, Rockman SP, Brooks AG, Reading PC, 2015. Infection of mouse macrophages by seasonal influenza viruses can Be restricted at the level of virus entry and at a late stage in the virus life cycle. J. Virol 89, 12319–12329. 10.1128/JVI.01455-15. PubMed DOI PMC

Londrigan SL, Wakim LM, Smith J, Haverkate AJ, Brooks AG, Reading PC, 2020. IFITM3 and type I interferons are important for the control of influenza A virus replication in murine macrophages. Virology 540, 17–22. 10.1016/j.virol.2019.11.003. PubMed DOI

Long Q, Yan R, Hu J, Cai D, Mitra B, Kim ES, Marchetti A, Zhang H, Wang S, Liu Y, Huang A, Guo H, 2017. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog. 13, e1006784. 10.1371/journal.ppat.1006784. PubMed DOI PMC

Ludwig S, Pleschka S, Planz O, 2023. MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases. Curr. Opin. Virol 59, 101304. 10.1016/j.coviro.2023.101304. PubMed DOI PMC

Luo J, Luckenbaugh L, Hu H, Yan Z, Gao L, Hu J, 2020. Involvement of host ATR-CHK1 pathway in hepatitis B virus covalently closed circular DNA formation. mBio 11. 10.1128/mBio.03423-19. PubMed DOI PMC

Ma JZ, Ng WC, Zappia L, Gearing LJ, Olshansky M, Pham K, Cheong K, Hsu A, Turner SJ, Wijburg O, Londrigan SL, Brooks AG, Reading PC, 2019. Unique transcriptional architecture in airway epithelial cells and macrophages shapes distinct responses following influenza virus infection ex vivo. J. Virol 93. 10.1128/JVI.01986-18. PubMed DOI PMC

Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, Liu X, Zhan P, 2021. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem. Soc. Rev 50, 4514–4540. 10.1039/d0cs01084g. PubMed DOI

Maeda H, Haneda K, Honda Y, 2017. Parainfluenza virus type 3 outbreak in a neonatal intensive care unit. Pediatr. Int 59, 1219–1222. 10.1111/ped.13389. PubMed DOI PMC

Marchetti AL, Zhang H, Kim ES, Yu X, Jang S, Wang M, Guo H, 2022. Proteomic analysis of nuclear hepatitis B virus relaxed circular DNA-associated proteins identifies UV-damaged DNA binding protein as a host factor involved in covalently closed circular DNA formation. J. Virol 96, e0136021. 10.1128/JVI.01360-21. PubMed DOI PMC

Marcink TC, Zipursky G, Cheng W, Stearns K, Stenglein S, Golub K, Cohen F, Bovier F, Pfalmer D, Greninger AL, Porotto M, Georges A, Moscona A, des Georges A, Moscona A, 2023. Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms. Sci. Adv 9, eade2727. 10.1126/sciadv.ade2727. PubMed DOI PMC

Martin H-J, Melo-Filho CC, Korn D, Eastman RT, Rai G, Simeonov A, Zakharov AV, Muratov E, Tropsha A, 2023. Small molecule antiviral compound collection (SMACC): a comprehensive, highly curated database to support the discovery of broad-spectrum antiviral drug molecules. Antivir. Res 217, 105620. 10.1016/j.antiviral.2023.105620. PubMed DOI PMC

Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MARB, Porotto M, Santos NC, Moscona A, 2017. Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. Sci. Rep 7, 43610. 10.1038/srep43610. PubMed DOI PMC

McCoullough LC, Fareh M, Hu W, Sozzi V, Makhlouf C, Droungas Y, Lee CL, Takawy M, Fabb SA, Payne TJ, Pouton CW, Netter HJ, Lewin SR, Purcell DF, Holmes JA, Trapani JA, Littlejohn M, Revill PA, 2024. CRISPR-Cas13b-mediated suppression of hepatitis B virus replication and protein expression. J. Hepatol 10.1016/j.jhep.2024.05.025. PubMed DOI

McMillan RE, Lo MK, Zhang X-Q, Beadle JR, Valiaeva N, Garretson AF, Clark AE, Freshman JE, Murphy J, Montgomery JM, Spiropoulou CF, Schooley RT, Hostetler KY, Carlin AF, 2023. Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs. Antivir. Res 219, 105718. 10.1016/j.antiviral.2023.105718. PubMed DOI PMC

Meischel T, Fritzlar S, Villalon-Letelier F, Tessema MB, Brooks AG, Reading PC, Londrigan SL, 2021. IFITM proteins that restrict the early stages of respiratory virus infection do not influence late-stage replication. J. Virol 95, e0083721. 10.1128/JVI.00837-21. PubMed DOI PMC

Meischel T, Villalon-Letelier F, Saunders PM, Reading PC, Londrigan SL, 2020. Influenza A virus interactions with macrophages: lessons from epithelial cells. Cell Microbiol. 22, e13170. 10.1111/cmi.13170. PubMed DOI

Mello C, Aguayo E, Rodriguez M, Lee G, Jordan R, Cihlar T, Birkus G, 2014. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob. Agents Chemother 58, 1546–1555. 10.1128/AAC.01746-13. PubMed DOI PMC

Melo-Filho CC, Bobrowski T, Martin H-J, Sessions Z, Popov KI, Moorman NJ, Baric RS, Muratov EN, Tropsha A, 2022. Conserved coronavirus proteins as targets of broad-spectrum antivirals. Antivir. Res 204, 105360. 10.1016/j.antiviral.2022.105360. PubMed DOI PMC

CITIID-NIHR BioResource COVID-19 Collaboration, Genotype to Phenotype Japan (G2P-Japan) Consortium, Ecuador-COVID19 Consortium, Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ, Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer KB, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK, 2022. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706–714. 10.1038/s41586-022-04474-x. PubMed DOI PMC

Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, Imhof H, Grimm D, Steiger K, Mogler C, Heikenwalder M, Michel M-L, Guzman CA, Milstein S, Sepp-Lorenzino L, Knolle P, Protzer U, 2020. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology 158, 1762–1775.e9. 10.1053/j.gastro.2020.01.032. PubMed DOI

Moquin SA, Simon O, Karuna R, Lakshminarayana SB, Yokokawa F, Wang F, Saravanan C, Zhang J, Day CW, Chan K, Wang Q-Y, Lu S, Dong H, Wan KF, Lim SP, Liu W, Seh CC, Chen Y-L, Xu H, Barkan DT, Kounde CS, Sim WLS, Wang G, Yeo H-Q, Zou B, Chan WL, Ding M, Song J-G, Li M, Osborne C, Blasco F, Sarko C, Beer D, Bonamy GMC, Sasseville VG, Shi P-Y, Diagana TT, Yeung BKS, Gu F, 2021. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci. Transl. Med 13. 10.1126/scitranslmed.abb2181. PubMed DOI

Mykytyn AZ, Breugem TI, Geurts MH, Beumer J, Schipper D, van Acker R, van den Doel PB, van Royen ME, Zhang J, Clevers H, Haagmans BL, Lamers MM, 2023. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models. J. Virol 97, e0085123. 10.1128/jvi.00851-23. PubMed DOI PMC

Mykytyn AZ, Breugem TI, Riesebosch S, Schipper D, van den Doel PB, Rottier RJ, Lamers MM, Haagmans BL, 2021. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. Elife 10. 10.7554/eLife.64508. PubMed DOI PMC

Nencka R, Silhan J, Klima M, Otava T, Kocek H, Krafcikova P, Boura E, 2022. Coronaviral RNA-methyltransferases: function, structure and inhibition. Nucleic Acids Res. 50, 635–650. 10.1093/nar/gkab1279. PubMed DOI PMC

Nimgaonkar I, Ding Q, Schwartz RE, Ploss A, 2018. Hepatitis E virus: advances and challenges. Nat. Rev. Gastroenterol. Hepatol 15, 96–110. 10.1038/nrgastro.2017.150. PubMed DOI PMC

Otava T, Šála M, Li F, Fanfrlík J, Devkota K, Perveen S, Chau I, Pakarian P, Hobza P, Vedadi M, Boura E, Nencka R, 2021. The structure-based design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors. ACS Infect. Dis 7, 2214–2220. 10.1021/acsinfecdis.1c00131. PubMed DOI

Outlaw VK, Cheloha RW, Jurgens EM, Bovier FT, Zhu Y, Kreitler DF, Harder O, Niewiesk S, Porotto M, Gellman SH, Moscona A, 2021. Engineering protease-resistant peptides to inhibit human parainfluenza viral respiratory infection. J. Am. Chem. Soc 143, 5958–5966. 10.1021/jacs.1c01565. PubMed DOI PMC

Outlaw VK, Kreitler DF, Stelitano D, Porotto M, Moscona A, Gellman SH, 2020. Effects of single α-to-β residue replacements on recognition of an extended segment in a viral fusion protein. ACS Infect. Dis 6, 2017–2022. 10.1021/acsinfecdis.0c00385. PubMed DOI PMC

Owens K, Esmaeili S, Schiffer JT, 2024. Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses. JCI insight 9. 10.1172/jci.insight.176286. PubMed DOI PMC

Park GJ, Osinski A, Hernandez G, Eitson JL, Majumdar A, Tonelli M, Henzler-Wildman K, Pawłowski K, Chen Z, Li Y, Schoggins JW, Tagliabracci VS, 2022. The mechanism of RNA capping by SARS-CoV-2. Nature 609, 793–800. 10.1038/s41586-022-05185-z. PubMed DOI PMC

Porotto M, Rockx B, Yokoyama CC, Talekar A, Devito I, Palermo LM, Liu J, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A, 2010. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 6, e1001168. 10.1371/journal.ppat.1001168. PubMed DOI PMC

Prodger JL, Capoferri AA, Yu K, Lai J, Reynolds SJ, Kasule J, Kityamuweesi T, Buule P, Serwadda D, Kwon KJ, Schlusser K, Martens C, Scully E, Choi Y-H, Redd AD, Quinn TC, 2020. Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai. Uganda. JCI Insight 5. 10.1172/jci.insight.139287. PubMed DOI PMC

Pshenichnaya NY, Sydenko IS, Klinovaya EP, Romanova EB, Zhuravlev AS, 2016. Possible sexual transmission of Crimean-Congo hemorrhagic fever. Int. J. Infect. Dis 45, 109–111. 10.1016/j.ijid.2016.02.1008. PubMed DOI

Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, Yao Q, Sun G, Liu Y, Tang D, Song Z, He W, Sun Y, Guo J-T, Li W, 2016. DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 12, e1005893. 10.1371/journal.ppat.1005893. PubMed DOI PMC

Rabbani MAG, Ribaudo M, Guo J-T, Barik S, 2016. Identification of interferon-stimulated gene proteins that inhibit human parainfluenza virus type 3. J. Virol 90, 11145–11156. 10.1128/JVI.01551-16. PubMed DOI PMC

Rath M, Wellnitz J, Martin H-J, Melo-Filho C, Hochuli JE, Silva GM, Beasley JM, Travis M, Sessions ZL, Popov KI, Zakharov AV, Cherkasov A, Alves V, Muratov EN, Tropsha A, 2024. Pharmacokinetics profiler (PhaKinPro): model development, validation, and implementation as a web tool for triaging compounds with undesired pharmacokinetics profiles. J. Med. Chem 67, 6508–6518. 10.1021/acs.jmedchem.3c02446. PubMed DOI

Ren Y, Huang SH, Patel S, Alberto WDC, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RB, 2020. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J. Clin. Invest 130, 2542–2559. 10.1172/JCI132374. PubMed DOI PMC

Rohde G, Stenglein S, Prozesky H, Manudhane G, Sandulescu O, Bauer M, Overend T, Koch W, Neuschwander D, Planz O, Torres A, Witzenrath M, 2023. Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial. EClinicalMedicine 65, 102237. 10.1016/j.eclinm.2023.102237. PubMed DOI PMC

Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523–527. 10.1038/nature07106. PubMed DOI PMC

Santos-Ferreira N, Van Dycke J, Chiu W, Neyts J, Matthijnssens J, Rocha-Pereira J, 2024. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids. Antivir. Res 223, 105839. 10.1016/j.antiviral.2024.105839. PubMed DOI

Schang LM, Hu M, Cortes EF, Sun K, 2021. Chromatin-mediated epigenetic regulation of HSV-1 transcription as a potential target in antiviral therapy. Antivir. Res 192, 105103. 10.1016/j.antiviral.2021.105103. PubMed DOI PMC

Schnell G, Loo Y-MM, Marcotrigiano J, Gale M, 2012. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog. 8, e1002839. 10.1371/journal.ppat.1002839. PubMed DOI PMC

Scholte FEM, Spengler JR, Welch SR, Harmon JR, Coleman-McCray JD, Freitas BT, Kainulainen MH, Pegan SD, Nichol ST, Bergeron É, Spiropoulou CF, 2019. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerg. Microb. Infect 8, 575–578. 10.1080/22221751.2019.1601030. PubMed DOI PMC

Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang X-Q, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY, 2021. Rethinking remdesivir: synthesis, antiviral activity, and pharmacokinetics of oral lipid prodrugs. Antimicrob. Agents Chemother 65, e0115521. 10.1128/AAC.01155-21. PubMed DOI PMC

Schreiber A, Ambrosy B, Planz O, Schloer S, Rescher U, Ludwig S, 2022a. The MEK1/2 inhibitor ATR-002 (zapnometinib) synergistically potentiates the antiviral effect of direct-acting anti-SARS-CoV-2 drugs. Pharmaceutics 14. 10.3390/pharmaceutics14091776. PubMed DOI PMC

Schreiber A, Boff L, Anhlan D, Krischuns T, Brunotte L, Schuberth C, Wedlich-Söldner R, Drexler H, Ludwig S, 2020. Dissecting the mechanism of signaling-triggered nuclear export of newly synthesized influenza virus ribonucleoprotein complexes. Proc. Natl. Acad. Sci. U.S.A 117, 16557–16566. 10.1073/pnas.2002828117. PubMed DOI PMC

Schreiber A, Rodner F, Oberberg N, Anhlan D, Bletz S, Mellmann A, Planz O, Ludwig S, 2024. The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance. Antivir. Res 225, 105840. 10.1016/j.antiviral.2024.105840. PubMed DOI

Schreiber A, Viemann D, Schöning J, Schloer S, Mecate Zambrano A, Brunotte L, Faist A, Schöfbänker M, Hrincius E, Hoffmann H, Hoffmann M, Pöhlmann S, Rescher U, Planz O, Ludwig S, 2022b. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Cell. Mol. Life Sci 79, 65. 10.1007/s00018-021-04085-1. PubMed DOI PMC

Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG, 2019. Sex-based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation. J. Infect. Dis 219, 1084–1094. 10.1093/infdis/jiy617. PubMed DOI PMC

Sessions Z, Bobrowski T, Martin H-J, Beasley J-MT, Kothari A, Phares T, Li M, Alves VM, Scotti MT, Moorman NJ, Baric R, Tropsha A, Muratov EN, 2023. Praemonitus praemunitus : can we forecast and prepare for future viral disease outbreaks? FEMS Microbiol. Rev 47. 10.1093/femsre/fuad048. PubMed DOI PMC

Sheraz M, Cheng J, Tang L, Chang J, Guo J-T, 2019. Cellular DNA topoisomerases are required for the synthesis of hepatitis B virus covalently closed circular DNA. J. Virol 93. 10.1128/JVI.02230-18. PubMed DOI PMC

Shi M, Lin X-D, Chen X, Tian J-H, Chen L-J, Li K, Wang W, Eden J-S, Shen J-J, Liu L, Holmes EC, Zhang Y-Z, 2018. The evolutionary history of vertebrate RNA viruses. Nature 556, 197–202. 10.1038/s41586-018-0012-7. PubMed DOI

Silhan J, Klima M, Otava T, Skvara P, Chalupska D, Chalupsky K, Kozic J, Nencka R, Boura E, 2023. Discovery and structural characterization of monkeypox virus methyltransferase VP39 inhibitors reveal similarities to SARS-CoV-2 nsp14 methyltransferase. Nat. Commun 14, 2259. 10.1038/s41467-023-38019-1. PubMed DOI PMC

Slanina H, Madhugiri R, Bylapudi G, Schultheiß K, Karl N, Gulyaeva A, Gorbalenya AE, Linne U, Ziebuhr J, 2021. Coronavirus replication-transcription complex: vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. Proc. Natl. Acad. Sci. U.S.A 118. 10.1073/pnas.2022310118. PubMed DOI PMC

Small GI, Fedorova O, Olinares PDB, Chandanani J, Banerjee A, Choi YJ, Molina H, Chait BT, Darst SA, Campbell EA, 2023. Structural and functional insights into the enzymatic plasticity of the SARS-CoV-2 NiRAN domain. Mol. Cell 83, 3921–3930.e7. 10.1016/j.molcel.2023.10.001. PubMed DOI PMC

Smekalova EM, Martinez MG, Combe E, Kumar A, Dejene S, Leboeuf D, Chen C-Y, Dorkin JR, Shuang LS, Kieft S, Young L, Barrera LA, Packer MS, Ciaramella G, Testoni B, Gregoire F, Zoulim F, 2024. Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo. Mol. Ther. Nucleic Acids 35, 102112. 10.1016/j.omtn.2023.102112. PubMed DOI PMC

Spengler JR, Carter K, Delang L, Durantel D, Gowen BB, Herrero LJ, Hurst B, Janeba Z, Jordan R, Luo D, Meier C, Moffat J, Rocha-Pereira J, Seley-Radtke KL, Welch SR, Schang LM, 2023. Meeting report: 36th international conference on antiviral research in Lyon, France - March 13–17, 2023. Antivir. Res 217, 105678. 10.1016/j.antiviral.2023.105678. PubMed DOI PMC

Spengler JR, Welch SR, Deval J, Gentry BG, Brancale A, Carter K, Moffat J, Meier C, Seley-Radtke KL, Schang LM, 2022. Meeting report: 35th international conference on antiviral research in Seattle, Washington, USA - March 21–25, 2022. Antivir. Res 211, 105521. 10.1016/j.antiviral.2022.105521. PubMed DOI PMC

Štefek M, Chalupská D, Chalupský K, Zgarbová M, Dvořáková A, Krafčíková P, Li ASM, Šála M, Dejmek M, Otava T, Chaloupecká E, Kozák J, Kozic J, Vedadi M, Weber J, Mertlíková-Kaiserová H, Nencka R, 2023. Rational design of highly potent SARS-CoV-2 nsp14 methyltransferase inhibitors. ACS Omega 8, 27410–27418. 10.1021/acsomega.3c02815. PubMed DOI PMC

Suschak JJ, Golden JW, Fitzpatrick CJ, Shoemaker CJ, Badger CV, Schmaljohn CS, Garrison AR, 2021. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. npj Vaccines 6, 31. 10.1038/s41541-021-00293-9. PubMed DOI PMC

Tan B, Zhang X, Ansari A, Jadhav P, Tan H, Li K, Chopra A, Ford A, Chi X, Ruiz FX, Arnold E, Deng X, Wang J, 2024. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434–1440. 10.1126/science.adm9724. PubMed DOI

Tan H, Hu Y, Jadhav P, Tan B, Wang J, 2022. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem 65, 7561–7580. 10.1021/acs.jmedchem.2c00303. PubMed DOI PMC

Tanaka K, Kim Y, Roche M, Lewin SR, 2022. The role of latency reversal in HIV cure strategies. J. Med. Primatol 51, 278–283. 10.1111/jmp.12613. PubMed DOI PMC

Tang L, Sheraz M, McGrane M, Chang J, Guo J-T, 2019. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathog. 15, e1007742. 10.1371/journal.ppat.1007742. PubMed DOI PMC

Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA, 2011. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3, 920–940. 10.3390/v3060920. PubMed DOI PMC

Tramontano E, Tarbet B, Spengler JR, Seley-Radtke K, Meier C, Jordan R, Janeba Z, Gowen B, Gentry B, Esté JA, Bray M, Andrei G, Schang LM, International society for antiviral research, 2019. Meeting report: 32nd international conference on antiviral research. Antivir. Res. 169, 104550. doi:10.1016/j.antiviral.2019.104550. PubMed DOI PMC

Trepte P, Secker C, Olivet J, Blavier J, Kostova S, Maseko SB, Minia I, Silva Ramos E, Cassonnet P, Golusik S, Zenkner M, Beetz S, Liebich MJ, Scharek N, Schütz A, Sperling M, Lisurek M, Wang Y, Spirohn K, Hao T, Calderwood MA, Hill DE, Landthaler M, Choi SG, Twizere J-C, Vidal M, Wanker EE, 2024. AI-guided pipeline for protein-protein interaction drug discovery identifies a SARS-CoV-2 inhibitor. Mol. Syst. Biol 20, 428–457. 10.1038/s44320-024-00019-8. PubMed DOI PMC

Van Den Bergh A, Bailly B, Guillon P, von Itzstein M, Dirr L, 2024. Novel insights into the host cell glycan binding profile of human metapneumovirus. J. Virol 98, e0164123. 10.1128/jvi.01641-23. PubMed DOI PMC

Van Den Bergh A, Bailly B, Guillon P, von Itzstein M, Dirr L, 2022a. Antiviral strategies against human metapneumovirus: targeting the fusion protein. Antivir. Res 207, 105405. 10.1016/j.antiviral.2022.105405. PubMed DOI

Van Den Bergh A, Guillon P, von Itzstein M, Bailly B, Dirr L, 2022b. Drug repurposing for therapeutic discovery against human metapneumovirus infection. Antimicrob. Agents Chemother 66, e0100822. 10.1128/aac.01008-22. PubMed DOI PMC

Van Dycke J, Dai W, Stylianidou Z, Li J, Cuvry A, Roux E, Li B, Rymenants J, Bervoets L, de Witte P, Liu H, Neyts J, Rocha-Pereira J, 2021. A novel class of norovirus inhibitors targeting the viral protease with potent antiviral activity in vitro and in vivo. Viruses 13. 10.3390/v13091852. PubMed DOI PMC

Vere Hodge A, 2011. Scientific report: highlights of 24th ICAR, 8–11 may 2011, sofia, Bulgaria. Antivir. Chem. Chemother 22, 75–85. 10.3851/IMP1885. PubMed DOI

Vere Hodge A, 2003a. Antiviral research–16th annual international conference. Satellite symposium: clinical update on antiviral drugs. 27 april-1 may 2003, Savannah, GA, USA. Idrugs 6, 515–517. PubMed

Vere Hodge A, 2003b. Antiviral research–16th international conference: 27 April-1 May 2003, Savannah, GA, USA. Idrugs 6, 512–514. PubMed

Vere Hodge RA, 2017. Meeting report: 29th international conference on antiviral research in La Jolla, CA, USA. Antivir. Res 137, 23–40. 10.1016/j.antiviral.2016.10.014. PubMed DOI PMC

Vere Hodge RA, 2015. Meeting report: 28th international conference on antiviral research in Rome, Italy. Antivir. Res 123, 172–187. 10.1016/j.antiviral.2015.09.015. PubMed DOI PMC

Vere Hodge RA, 2014. Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA. Antivir. Res 111, 143–153. 10.1016/j.antiviral.2014.08.009. PubMed DOI PMC

Vere Hodge RA, 2013. Meeting report: 26th international conference on antiviral research. Antivir. Res 100, 276–285. 10.1016/j.antiviral.2013.08.006. PubMed DOI PMC

Voss S, Rademann J, Nitsche C, 2024. Characterisation of ten NS2B-NS3 proteases: paving the way for pan-flavivirus drugs. Antivir. Res 226, 105878. 10.1016/j.antiviral.2024.105878. PubMed DOI

Wang AC, Pham HT, Lipps JM, Brittain SM, Harrington E, Wang Y, King FJ, Russ C, Pan X, Hoepfner D, Tallarico J, Feng Y, Jain RK, Schirle M, Thomas JR, 2019. Previously uncharacterized vacuolar-type ATPase binding site discovered from structurally similar compounds with distinct mechanisms of action. ACS Chem. Biol 14, 20–26. 10.1021/acschembio.8b00656. PubMed DOI

Wang G, Dyatkina N, Prhavc M, Williams C, Serebryany V, Hu Y, Huang Y, Wu X, Chen T, Huang W, Rajwanshi VK, Deval J, Fung A, Jin Z, Stoycheva A, Shaw K, Gupta K, Tam Y, Jekle A, Smith DB, Beigelman L, 2020. Synthesis and anti-HCV activity of sugar-modified guanosine analogues: discovery of AL-611 as an HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C. J. Med. Chem 63, 10380–10395. 10.1021/acs.jmedchem.0c00935. PubMed DOI

Wang H, Li K, Cui B, Yan H, Wu S, Wang K, Yang G, Jiang J, Li Y, 2024. Tribbles pseudokinase 3 promotes enterovirus A71 infection via dual mechanisms. Emerg. Microb. Infect 13, 2307514. 10.1080/22221751.2024.2307514. PubMed DOI PMC

Wei L, Ploss A, 2020. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat. Microbiol 5, 715–726. 10.1038/s41564-020-0678-0. PubMed DOI PMC

Welch SR, Guerrero LW, Chakrabarti AK, McMullan LK, Flint M, Bluemling GR, Painter GR, Nichol ST, Spiropoulou CF, Albarino CG, Albariño CG, 2016. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antivir. Res 136, 9–18. 10.1016/j.antiviral.2016.10.007. PubMed DOI

Welch SR, Ritter JM, McElroy AK, Harmon JR, Coleman-McCray JD, Scholte FEM, Kobinger GP, Bergeron É, Zaki SR, Nichol ST, Spengler JR, Spiropoulou CF, 2019. Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in IFNAR−/− mice. PLoS Pathog. 15, e1008183. 10.1371/journal.ppat.1008183. PubMed DOI PMC

Welch SR, Spengler JR, Genzer SC, Coleman-McCray JD, Harmon JR, Sorvillo TE, Scholte FEM, Rodriguez SE, O’Neal TJ, Ritter JM, Ficarra G, Davies KA, Kainulainen MH, Karaaslan E, Bergeron É, Goldsmith CS, Lo MK, Nichol ST, Montgomery JM, Spiropoulou CF, 2023. Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination. Sci. Adv 9, eadh4057. 10.1126/sciadv.adh4057. PubMed DOI PMC

Westover JB, Jung KH, Alkan C, Boardman KM, Van Wettere AJ, Martens C, Rojas I, Hicks P, Thomas AJ, Saindane MT, Bluemling GR, Mao S, Kolykhalov AA, Natchus MG, Bates P, Painter GR, Ikegami T, Gowen BB, 2024. Modeling Heartland virus disease in mice and therapeutic intervention with 4’-fluorouridine. J. Virol 98, e0013224. 10.1128/jvi.00132-24. PubMed DOI PMC

WHO, W.H.O., 2024. Global hepatitis report 2024: action for access in low- and middle-income countries. https://www.who.int/publications/i/item/9789240091672, 7.7.24.

PITCH Consortium, COVID-19 Genomics UK (COG-UK) Consortium, Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, Manali M, Szemiel A, Cowton V, Vink E, Harvey WT, Davis C, Asamaphan P, Smollett K, Tong L, Orton R, Hughes J, Holland P, Silva V, Pascall DJ, Puxty K, da Silva Filipe A, Yebra G, Shaaban S, Holden MTG, Pinto RM, Gunson R, Templeton K, Murcia PR, Patel AH, Klenerman P, Dunachie S, Haughney J, Robertson DL, Palmarini M, Ray S, Thomson EC, 2022. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol 7, 1161–1179. 10.1038/s41564-022-01143-7. PubMed DOI PMC

Xie S, Zhu J, Li J, Zhan F, Yao H, Xu J, Xu S, 2023. Small-molecule hydrophobic tagging: a promising strategy of druglike technology for targeted protein degradation. J. Med. Chem 66, 10917–10933. 10.1021/acs.jmedchem.3c00736. PubMed DOI

Xie X, Lan Q, Zhao J, Zhang S, Liu L, Zhang Y, Xu W, Shao M, Peng J, Xia S, Zhu Y, Zhang K, Zhang X, Zhang R, Li J, Dai W, Ge Z, Hu S, Yu C, Wang J, Ma D, Zheng M, Yang H, Xiao G, Rao Z, Lu L, Zhang L, Bai F, Zhao Y, Jiang S, Liu H, 2024. Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1. Signal Transduct. Targeted Ther 9, 54. 10.1038/s41392-024-01758-8. PubMed DOI PMC

Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE, Aguilar PV, Plante KS, Weaver SC, Makino S, LeDuc JW, Menachery VD, Shi P-Y, 2020. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841–848.e3. 10.1016/j.chom.2020.04.004. PubMed DOI PMC

Yang Y-C, Chen Y-H, Kao J-H, Ching C, Liu I-J, Wang C-C, Tsai C-H, Wu F-Y, Liu C-J, Chen P-J, Chen D-S, Yang H-C, 2020. Permanent inactivation of HBV genomes by CRISPR/Cas9-Mediated non-cleavage base editing. Mol. Ther. Nucleic Acids 20, 480–490. 10.1016/j.omtn.2020.03.005. PubMed DOI PMC

Ye Z-W, Ong CP, Tang K, Fan Y, Luo C, Zhou R, Luo P, Cheng Y, Gray VS, Wang P, Chu H, Chan JF-W, To KK-W, Chen H, Chen Z, Yuen K-Y, Ling GS, Yuan S, Jin D-Y, 2022. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. Cell. Mol. Immunol 19, 588–601. 10.1038/s41423-022-00855-4. PubMed DOI PMC

Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H, 2024. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw. Open 7, e2354991. 10.1001/jamanetworkopen.2023.54991. PubMed DOI PMC

Yu X, Long Q, Shen S, Liu Z, Chandran J, Zhang J, Ding H, Zhang H, Cai D, Kim ES, Huang Y, Guo H, 2023. Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription. Antivir. Res 211, 105552. 10.1016/j.antiviral.2023.105552. PubMed DOI PMC

Zgarbová M, Otava T, Silhan J, Nencka R, Weber J, Boura E, 2023. Inhibitors of mpox VP39 2’-O methyltransferase efficiently inhibit the monkeypox virus. Antivir. Res 218, 105714. 10.1016/j.antiviral.2023.105714. PubMed DOI

Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, von Brunn A, Leyssen P, Lanko K, Neyts J, de Wilde A, Snijder EJ, Liu H, Hilgenfeld R, 2020. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J. Med. Chem 63, 4562–4578. 10.1021/acs.jmedchem.9b01828. PubMed DOI

Zhang X-A, Li H, Jiang F-C, Zhu F, Zhang Y-F, Chen J-J, Tan C-W, Anderson DE, Fan H, Dong L-Y, Li C, Zhang P-H, Li Y, Ding H, Fang L-Q, Wang L-F, Liu W, 2022. A zoonotic henipavirus in febrile patients in China. N. Engl. J. Med 387, 470–472. 10.1056/NEJMc2202705. PubMed DOI